Search results for "Unknown"

showing 10 items of 445 documents

CCDC 1861473: Experimental Crystal Structure Determination

2018

Related Article: Chris Gendy, Akseli Mansikkamäki, Juuso Valjus, Joshua Heidebrecht, Paul Chuk-Yan Hui, Guy M. Bernard, Heikki M. Tuononen, Roderick E. Wasylishen, Vladimir K. Michaelis, Roland Roesler|2019|Angew.Chem.,Int.Ed.|58|154|doi:10.1002/anie.201809889

(11'-[(1133-tetramethyldisiloxane-13-diyl)bis(methylene)]bis{3-[26-bis(propan-2-yl)phenyl]-imidazol-2-ylidene})-dichloro-germanium-nickel(0) toluene unknown solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2131014: Experimental Crystal Structure Determination

2022

Related Article: Braulio M. Puerta Lombardi, Ethan R. Pezoulas, Roope A. Suvinen, Alexander Harrison, Zachary S. Dubrawski, Benjamin S. Gelfand, Heikki M. Tuononen, Roland Roesler|2022|Chem.Commun.|58|6482|doi:10.1039/D2CC01476A

(18-bis[26-bis(propan-2-yl)phenyl]-2277-tetramethyl-12345678-octahydro-3a5a-ethanopyrrolo[32-g]indol-1-ium radical) tetrafluoroborate unknown solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2124204: Experimental Crystal Structure Determination

2022

Related Article: Wenhua Lin, Ming Liu, Lei Xu, Yanping Ma, Liping Zhang, Zygmunt Flisak, Xinquan Hu, Tongling Liang, Wen‐Hua Sun|2022|Appl.Organomet.Chem.|36|e6596|doi:10.1002/aoc.6596

(N2-dimesityl-67-dihydroquinolin-8(5H)-imine)-dibromo-nickel(ii) unknown solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1874714: Experimental Crystal Structure Determination

2019

Related Article: Biswanath Das, Afnan Al-Hunaiti, Brenda N. S��nchez-Egu��a, Erica Zeglio, Serhiy Demeshko, Sebastian Dechert, Steffen Braunger, Matti Haukka, Timo Repo, Ivan Castillo, Ebbe Nordlander|2019|Frontiers in Chemistry|7|97|doi:10.3389/fchem.2019.00097

(mu-oxo)-bis(mu-formato)-bis(2-[(24-dimethylphenyl)sulfanyl]-NN-bis[(1-methyl-1H-benzimidazol-2-yl)methyl]ethan-1-amine)-di-iron(iii) bis(perchlorate) methanol unknown solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1919442: Experimental Crystal Structure Determination

2019

Related Article: Jana Anhäuser, Rakesh Puttreddy, Lukas Glanz, Andreas Schneider, Marianne Engeser, Kari Rissanen, Arne Lützen|2019|Chem.-Eur.J.|25|12294|doi:10.1002/chem.201903164

(rac)-hexakis(mu-NN'-[tricyclo[8.2.2.247]hexadeca-1(12)46101315-hexaene-512-diylbis(41-phenylene)]bis[1-(pyridin-2-yl)methanimine])-tetra-iron(ii) octakis(trifluoromethanesulfonate) unknown solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1919440: Experimental Crystal Structure Determination

2019

Related Article: Jana Anhäuser, Rakesh Puttreddy, Lukas Glanz, Andreas Schneider, Marianne Engeser, Kari Rissanen, Arne Lützen|2019|Chem.-Eur.J.|25|12294|doi:10.1002/chem.201903164

(ΔΔΔΔ)-hexakis(mu-(RP)-NN'-[tricyclo[8.2.2.247]hexadeca-1(12)46101315-hexaene-512-diylbis(41-phenylene)]bis[1-(pyridin-2-yl)methanimine])-tetra-iron(ii) octakis(trifluoromethanesulfonate) acetonitrile unknown solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.

2019

Introduction: Infections are among the most frequent complications in patients with hematological and oncological diseases. They might be classified as fever of unknown origin and microbiologically or clinically documented infections. Optimal duration of antimicrobial treatment is still unclear in these patients.Areas covered: We provide an overview on the management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.Expert opinion: Patients with febrile high-risk neutropenia should be treated empirically with an anti-pseudomonal agent such as piperacillin/tazobactam. Several clinical studies support the assumption that the primary antibiotic regime…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyAntifungal Agents030106 microbiologyNeutropeniaMicrobiologyTazobactam03 medical and health sciencesAntimicrobial Stewardship0302 clinical medicineAnti-Infective AgentsVirologyMedicineHumans030212 general & internal medicineFever of unknown originIntensive care medicineFebrile Neutropeniabusiness.industryDrug Resistance Microbialmedicine.diseaseAntimicrobialDrug Resistance MultipleDiscontinuationAnti-Bacterial AgentsInfectious DiseasesDrug Therapy CombinationbusinessFebrile neutropeniaDe-escalationmedicine.drugPiperacillinExpert review of anti-infective therapy
researchProduct

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report

2018

Melanoma is considered an aggressive malignancy with a tendency for forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of this disease. Melanoma brain metastases have many severe side effects and unfortunately, any disease related to the brain has limited therapeutic options due to the blood brain barrier. The course of the disease after completing a treatment course, and stopping the treatment, is complicated to predict and is difficult to obtain long-lasting remission. In this report we describe a female patient with un…

0301 basic medicineOncologyNasal cavityCancer Researchmedicine.medical_specialtyCentral nervous systemDiseaseMalignancyblood–brain barrierlcsh:RC254-282Metastasis03 medical and health sciences0302 clinical medicinemelanoma brain metastasisInternal medicinemedicineECHO-7 virusoncolytic virusbusiness.industryMelanomaintranasalmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncolytic virus030104 developmental biologymedicine.anatomical_structureOncologymelanoma unknown primary030220 oncology & carcinogenesisbusinessBrain metastasisFrontiers in Oncology
researchProduct

Melanoma of unknown primary: New perspectives for an old story

2021

Melanoma of unknown primary site (MUP) comprises 3-4 % of all melanomas. It mostly presents in lymph nodes (LNs), followed by subcutaneous sites, and visceral organs; nevertheless, there is a trend of increase in the relative incidence of visceral counterpart in recent years. Spontaneous regression of the primary lesion is a well-established theory, based on the evidence that melanoma can undergo regression at the primary site. MUP and stage-matched melanoma of known primary site (MKP) share similar prognostic factors. The survival rate of patients with MUP has been compared to those with stage-matched MKP. Multiple studies conducted before the era of novel therapy with immune checkpoint or…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatment2720 Hematology610 Medicine & healthTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineHumansMelanomaSurvival rateHematologybusiness.industryIncidenceMelanomaIncidence (epidemiology)General MedicineHematologyImmunotherapymedicine.disease10174 Clinic for GynecologyImmune checkpointSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplasms Unknown Primary2730 OncologyLymph NodesGeriatrics and GerontologybusinessCritical Reviews in Oncology/Hematology
researchProduct

CCDC 2061198: Experimental Crystal Structure Determination

2021

Related Article: Lauri Happonen, J. Mikko Rautiainen, Arto Valkonen|2021|Cryst.Growth Des.|21|3409|doi:10.1021/acs.cgd.1c00183

1245-tetrafluoro-36-di-iodobenzene bis(13-thiazolidine-2-thione) unknown solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct